Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients

Koji Kawamura, Rie Yamazaki, Yu Akahoshi, Hirofumi Nakano, Tomotaka Ugai, Hidenori Wada, Ryoko Yamasaki, Yuko Ishihara, Kana Sakamoto, Masahiro Ashizawa, Miki Sato, Kiriko Terasako-Saito, Shun Ichi Kimura, Misato Kikuchi, Hideki Nakasone, Junya Kanda, Shinichi Kako, Aki Tanihara, Junji Nishida, Yoshinobu Kanda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Previous studies have shown that most patients lose immunity to measles, mumps, and rubella (MMR) during long-term follow-up after allogeneic hematopoietic stem cell transplantation (HSCT), and immunizations against them have been investigated. However, these previous studies mainly targeted pediatric patients and information in adult patients is still insufficient. Methods: We evaluated the immunity to MMR in 45 adult allogeneic HSCT patients. None of these patients received vaccination after HSCT. Results: The seropositive rates at six years after allogeneic HSCT were estimated to be less than 44% for measles, less than 10% for mumps, and less than 36% for rubella. Thirteen of the 16 female patients who were 16–39 years old were negative or equivocal for rubella. Patients who developed grade II–IV acute graft-versus-host disease tended to become seronegative for measles and rubella at two years after HSCT, although the difference was not statistically significant. Conclusions: This study showed that most adult patients lost immunity to MMR after allogeneic HSCT. Although we did not evaluate the safety and efficacy of vaccination in this study, most HSCT guidelines recommend vaccination for HSCT recipients without active chronic graft-versus-host disease or ongoing immunosuppressive therapy at 24 months after HSCT. Immunization against rubella is especially important for female patients of reproductive age. Further studies will be necessary to evaluate the effect of vaccination on the antibody response in adult allogeneic HSCT recipients.

Original languageEnglish
Pages (from-to)77-82
Number of pages6
JournalHematology
Volume20
Issue number2
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Fingerprint

Mumps
Rubella
Hematopoietic Stem Cell Transplantation
Measles
Vaccination
Immunity
Graft vs Host Disease
Immunization
Immunosuppressive Agents
Antibody Formation
Guidelines
Pediatrics
Safety

Keywords

  • Allogeneic HSCT
  • Immunization
  • Measles
  • Mumps
  • Rubella

ASJC Scopus subject areas

  • Hematology

Cite this

Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients. / Kawamura, Koji; Yamazaki, Rie; Akahoshi, Yu; Nakano, Hirofumi; Ugai, Tomotaka; Wada, Hidenori; Yamasaki, Ryoko; Ishihara, Yuko; Sakamoto, Kana; Ashizawa, Masahiro; Sato, Miki; Terasako-Saito, Kiriko; Kimura, Shun Ichi; Kikuchi, Misato; Nakasone, Hideki; Kanda, Junya; Kako, Shinichi; Tanihara, Aki; Nishida, Junji; Kanda, Yoshinobu.

In: Hematology, Vol. 20, No. 2, 01.01.2015, p. 77-82.

Research output: Contribution to journalArticle

Kawamura, K, Yamazaki, R, Akahoshi, Y, Nakano, H, Ugai, T, Wada, H, Yamasaki, R, Ishihara, Y, Sakamoto, K, Ashizawa, M, Sato, M, Terasako-Saito, K, Kimura, SI, Kikuchi, M, Nakasone, H, Kanda, J, Kako, S, Tanihara, A, Nishida, J & Kanda, Y 2015, 'Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients', Hematology, vol. 20, no. 2, pp. 77-82. https://doi.org/10.1179/1607845414Y.0000000174
Kawamura, Koji ; Yamazaki, Rie ; Akahoshi, Yu ; Nakano, Hirofumi ; Ugai, Tomotaka ; Wada, Hidenori ; Yamasaki, Ryoko ; Ishihara, Yuko ; Sakamoto, Kana ; Ashizawa, Masahiro ; Sato, Miki ; Terasako-Saito, Kiriko ; Kimura, Shun Ichi ; Kikuchi, Misato ; Nakasone, Hideki ; Kanda, Junya ; Kako, Shinichi ; Tanihara, Aki ; Nishida, Junji ; Kanda, Yoshinobu. / Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients. In: Hematology. 2015 ; Vol. 20, No. 2. pp. 77-82.
@article{a340512466bc452397f7030c1b3bd3af,
title = "Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients",
abstract = "Background: Previous studies have shown that most patients lose immunity to measles, mumps, and rubella (MMR) during long-term follow-up after allogeneic hematopoietic stem cell transplantation (HSCT), and immunizations against them have been investigated. However, these previous studies mainly targeted pediatric patients and information in adult patients is still insufficient. Methods: We evaluated the immunity to MMR in 45 adult allogeneic HSCT patients. None of these patients received vaccination after HSCT. Results: The seropositive rates at six years after allogeneic HSCT were estimated to be less than 44{\%} for measles, less than 10{\%} for mumps, and less than 36{\%} for rubella. Thirteen of the 16 female patients who were 16–39 years old were negative or equivocal for rubella. Patients who developed grade II–IV acute graft-versus-host disease tended to become seronegative for measles and rubella at two years after HSCT, although the difference was not statistically significant. Conclusions: This study showed that most adult patients lost immunity to MMR after allogeneic HSCT. Although we did not evaluate the safety and efficacy of vaccination in this study, most HSCT guidelines recommend vaccination for HSCT recipients without active chronic graft-versus-host disease or ongoing immunosuppressive therapy at 24 months after HSCT. Immunization against rubella is especially important for female patients of reproductive age. Further studies will be necessary to evaluate the effect of vaccination on the antibody response in adult allogeneic HSCT recipients.",
keywords = "Allogeneic HSCT, Immunization, Measles, Mumps, Rubella",
author = "Koji Kawamura and Rie Yamazaki and Yu Akahoshi and Hirofumi Nakano and Tomotaka Ugai and Hidenori Wada and Ryoko Yamasaki and Yuko Ishihara and Kana Sakamoto and Masahiro Ashizawa and Miki Sato and Kiriko Terasako-Saito and Kimura, {Shun Ichi} and Misato Kikuchi and Hideki Nakasone and Junya Kanda and Shinichi Kako and Aki Tanihara and Junji Nishida and Yoshinobu Kanda",
year = "2015",
month = "1",
day = "1",
doi = "10.1179/1607845414Y.0000000174",
language = "English",
volume = "20",
pages = "77--82",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients

AU - Kawamura, Koji

AU - Yamazaki, Rie

AU - Akahoshi, Yu

AU - Nakano, Hirofumi

AU - Ugai, Tomotaka

AU - Wada, Hidenori

AU - Yamasaki, Ryoko

AU - Ishihara, Yuko

AU - Sakamoto, Kana

AU - Ashizawa, Masahiro

AU - Sato, Miki

AU - Terasako-Saito, Kiriko

AU - Kimura, Shun Ichi

AU - Kikuchi, Misato

AU - Nakasone, Hideki

AU - Kanda, Junya

AU - Kako, Shinichi

AU - Tanihara, Aki

AU - Nishida, Junji

AU - Kanda, Yoshinobu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Previous studies have shown that most patients lose immunity to measles, mumps, and rubella (MMR) during long-term follow-up after allogeneic hematopoietic stem cell transplantation (HSCT), and immunizations against them have been investigated. However, these previous studies mainly targeted pediatric patients and information in adult patients is still insufficient. Methods: We evaluated the immunity to MMR in 45 adult allogeneic HSCT patients. None of these patients received vaccination after HSCT. Results: The seropositive rates at six years after allogeneic HSCT were estimated to be less than 44% for measles, less than 10% for mumps, and less than 36% for rubella. Thirteen of the 16 female patients who were 16–39 years old were negative or equivocal for rubella. Patients who developed grade II–IV acute graft-versus-host disease tended to become seronegative for measles and rubella at two years after HSCT, although the difference was not statistically significant. Conclusions: This study showed that most adult patients lost immunity to MMR after allogeneic HSCT. Although we did not evaluate the safety and efficacy of vaccination in this study, most HSCT guidelines recommend vaccination for HSCT recipients without active chronic graft-versus-host disease or ongoing immunosuppressive therapy at 24 months after HSCT. Immunization against rubella is especially important for female patients of reproductive age. Further studies will be necessary to evaluate the effect of vaccination on the antibody response in adult allogeneic HSCT recipients.

AB - Background: Previous studies have shown that most patients lose immunity to measles, mumps, and rubella (MMR) during long-term follow-up after allogeneic hematopoietic stem cell transplantation (HSCT), and immunizations against them have been investigated. However, these previous studies mainly targeted pediatric patients and information in adult patients is still insufficient. Methods: We evaluated the immunity to MMR in 45 adult allogeneic HSCT patients. None of these patients received vaccination after HSCT. Results: The seropositive rates at six years after allogeneic HSCT were estimated to be less than 44% for measles, less than 10% for mumps, and less than 36% for rubella. Thirteen of the 16 female patients who were 16–39 years old were negative or equivocal for rubella. Patients who developed grade II–IV acute graft-versus-host disease tended to become seronegative for measles and rubella at two years after HSCT, although the difference was not statistically significant. Conclusions: This study showed that most adult patients lost immunity to MMR after allogeneic HSCT. Although we did not evaluate the safety and efficacy of vaccination in this study, most HSCT guidelines recommend vaccination for HSCT recipients without active chronic graft-versus-host disease or ongoing immunosuppressive therapy at 24 months after HSCT. Immunization against rubella is especially important for female patients of reproductive age. Further studies will be necessary to evaluate the effect of vaccination on the antibody response in adult allogeneic HSCT recipients.

KW - Allogeneic HSCT

KW - Immunization

KW - Measles

KW - Mumps

KW - Rubella

UR - http://www.scopus.com/inward/record.url?scp=84923365486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923365486&partnerID=8YFLogxK

U2 - 10.1179/1607845414Y.0000000174

DO - 10.1179/1607845414Y.0000000174

M3 - Article

VL - 20

SP - 77

EP - 82

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 2

ER -